Skip to main content

Advertisement

Log in

Current status of high-intensity focused ultrasound for prostate cancer: Technology, clinical outcomes, and future

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Based on a review of recently published articles, we evaluated the current status of high-intensity focused ultrasound (HIFU) as a primary treatment option for localized prostate cancer and as a salvage therapy when radiation has failed. With mid-and long-term progression-free survival rates around 70%, negative postoperative prostate biopsies almost 90%, and an excellent morbidity profile, primary HIFU appears to be a valid alternative to active surveillance protocols in low-risk patients and standard therapies in patients with life expectancies of 10 or fewer years. Moreover, HIFU has a considerable potential for local-only recurrence after radiation failure. HIFU is a recent technology, and many improvements will undoubtedly expand its future indications and use for the management of prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Sim HG, Cheng CW: Changing demography of prostate cancer in Asia. Eur J Cancer 2005, 41:834–845.

    Article  PubMed  Google Scholar 

  2. Grönberg H: Prostate cancer epidemiology. Lancet 2003, 361:859–864.

    Article  PubMed  Google Scholar 

  3. Boccon-Gibod LM, Dumonceau O, Toublang M, et al.: Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features. Eur Urol 2005, 48:895–899.

    Article  PubMed  CAS  Google Scholar 

  4. Adolfsson J, Tribukait B, Levitt S: The 20-yr outcome in patients with well-or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumor ploidy and comorbidity. Eur Urol 2007, 52:1028–1035.

    Article  PubMed  Google Scholar 

  5. Wong YN, Mitra N, Hudes G, et al.: Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 2006, 296:2683–2693.

    Article  PubMed  CAS  Google Scholar 

  6. Ter Haar G, Coussios C: High intensity focused ultrasound: physical principles and devices. Int J Hyperthermia 2007, 23:89–104.

    Article  PubMed  Google Scholar 

  7. Chapelon JY, Margonari J, Vernier F, et al.: In vivo effects of high-intensity ultrasound on prostate adenocarcinoma Dunning R3327. Cancer Res 1992, 52:6353–6357.

    PubMed  CAS  Google Scholar 

  8. Rouviere O, Lyonnet D, Raudrant A, et al.: MRI appearance of prostate following transrectal HIFU ablation of localized cancer. Eur Urol 2001, 40:265–274.

    Article  PubMed  CAS  Google Scholar 

  9. Rouviere O, Souchon R, Salomir R, et al.: Transrectal high-intensity focused ultrasound ablation of prostate cancer: Effective treatment requiring accurate imaging. Eur J Radiol 2007, 63:317–327.

    Article  PubMed  Google Scholar 

  10. De Senneville BD, Mougenot C, Moonen CT: Real-time methods for treatment of mobile organs by MRI-controlled high-intensity focused ultrasound. Magn Reson Med 2007, 57:319–330.

    Article  PubMed  Google Scholar 

  11. Illing RO, Leslie TA, Kennedy JE, et al.: Visually directed high-intensity focused ultrasound for organ-confined prostate cancer: a proposed standard for the conduct of therapy. BJU Int 2006, 98:1187–1192.

    Article  PubMed  Google Scholar 

  12. Ficarra V, Antoniolli SZ, Novara G, et al.: Short-term outcome after high-intensity focused ultrasound in the treatment of patients with high-risk prostate cancer. BJU Int 2006, 98:1193–1198.

    Article  PubMed  Google Scholar 

  13. Uchida T, Ohkusa H, Nagata Y, et al.: Treatment of localized prostate cancer using high-intensity focused ultrasound. BJU Int 2006, 97:56–61.

    Article  PubMed  Google Scholar 

  14. Blana A, Walter B, Rogenhofer S, Wieland WF: High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology 2004, 63:297–300.

    Article  PubMed  Google Scholar 

  15. Chaussy C, Thuroff S: The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep 2003, 4:248–252.

    Article  PubMed  Google Scholar 

  16. Lee HM, Hong JH, Choi HY: High-intensity focused ultrasound therapy for clinically localized prostate cancer. Prostate Cancer Prostatic Dis 2006, 9:439–443.

    Article  PubMed  CAS  Google Scholar 

  17. Poissonnier L, Chapelon JY, Rouviere O, et al.: Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 2007, 51:381–387.

    Article  PubMed  CAS  Google Scholar 

  18. Vallancien G, Prapotnich D, Cathelineau X, et al.: Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study. J Urol 2004, 171:2265–2267.

    Article  PubMed  Google Scholar 

  19. Thuroff S, Chaussy C, Vallancien G, et al.: High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J Endourol 2003, 17:673–677.

    Article  PubMed  Google Scholar 

  20. Uchida T, Ohkusa H, Yamashita H, et al.: Five years experience of transrectal high-intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer. Int J Urol 2006, 13:228–233.

    Article  PubMed  Google Scholar 

  21. Uchida T, Illing RO, Cathcart PJ, Emberton M: To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate? BJU Int 2006, 98:537–539.

    Article  PubMed  CAS  Google Scholar 

  22. Uchida T, Rowland O, Cathcart PJ, Emberton M: The effect of neoadjuvant androgen suppression on prostate-related outcomes after high-intensity focused ultrasound. BJU Int 2006, 98:770–772.

    Article  PubMed  CAS  Google Scholar 

  23. Blana A, Murat FJ, Walter B, et al.: First analysis of the long-term results with transrectal HIFU in patients with localized prostate cancer. Eur Urol 2007, In press.

  24. Rebillard X, Davin JL, Soulie M, Comite de cancerologie de l’Association Francaise d’Urologie: Treatment by HIFU of prostate cancer: survey of literature and treatment indications. Prog Urol 2003, 13:1428–1456.

    PubMed  Google Scholar 

  25. Madersbacher S, Pedevilla M, Vingers L, et al.: Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res 1995, 55:3346–3351.

    PubMed  CAS  Google Scholar 

  26. Gelet A, Chapelon JY, Bouvier R, et al.: Treatment of prostate cancer with transrectal focused ultrasound: early clinical experience. Eur Urol 1996, 29:174–183.

    PubMed  CAS  Google Scholar 

  27. Chaussy C, Thuroff S: Results and side effects of high-intensity focused ultrasound in localized prostate cancer. J Endourol 2001, 15:437–440.

    Article  PubMed  CAS  Google Scholar 

  28. Ganzer R, Rogenhofer S, Walter B, et al.: PSA nadir is a significant predictor of treatment failure after high intensity focused ultrasound (HIFU) treatment of localized prostate cancer. Eur Urol, 2007, In press.

  29. Gelet A, Chapelon JY, Bouvier R, et al.: Transrectal high intensity focused ultrasound for the treatment of localized prostate cancer: factors influencing the outcome. Eur Urol 2001, 40:124–129.

    Article  PubMed  CAS  Google Scholar 

  30. Chaussy C, Thuroff S: High-intensity focused ultrasound in localized prostate cancer. J Endourol 2000, 14:293–299.

    Article  PubMed  CAS  Google Scholar 

  31. Thuroff S, Chaussy C: High-intensity focused ultrasound: complications and adverse effects. Mol Urol 2000, 4:183–187.

    PubMed  CAS  Google Scholar 

  32. Chaussy C, Thuroff S, Rebillard X, Gelet A: Technology insight: high intensity focused ultrasound for urologic cancers. Nat Clin Pract Urol 2005, 2:191–198.

    Article  PubMed  Google Scholar 

  33. Blana A, Rogenhofer S, Ganzer R, et al.: Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer. World J Urol 2006, 24:585–590.

    Article  PubMed  Google Scholar 

  34. Pollack A, Hanlon AL, Horwitz EM, et al.: Prostate cancer radiotherapy dose response: an update of the Fox Chase experience. J Urol 2004, 171:1132–1136.

    Article  PubMed  Google Scholar 

  35. Shipley WU, Thames HD, Sandler HM, et al.: Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999, 281:1598–1604.

    Article  PubMed  CAS  Google Scholar 

  36. Zelefsky MJ, Kuban DA, Levy LB, et al.: Multi-institutional analysis of long-term outcome for stages T1–T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2005, 62:327–333.

    Google Scholar 

  37. Heinish M, Dirisamer A, Loidl W, et al.: Positron emission tomography/computed tomography with F-18-Fluorcholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml? Mol Imaging Biol 2006, 8:43–48.

    Article  Google Scholar 

  38. Harisinghani MG, Barentsz J, Hahn PF, et al.: Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003, 348:2491–2499.

    Article  PubMed  Google Scholar 

  39. Chaussy C, Thuroff S, Bergsdorf T: Local recurrence of prostate cancer after curative therapy. HIFU (Ablatherm) as a treatment option [in German]. Urologe 2006, 45:1271–1275.

    Article  PubMed  CAS  Google Scholar 

  40. Murat FJ, Poissonnier L, Rouviere O, et al.: Salvage high intensity focused ultrasound (HIFU) treatment for recurrent prostate cancer after radiation therapy: High efficacy in patients with good initial prognosis [abstract 1777]. J Urol 2007, 177:591.

    Google Scholar 

  41. Ross AB, Diederich CJ, Nau WH, et al.: Curvilinear transurethral ultrasound applicator for selective prostate thermal therapy. Med Phys 2005, 32:1555–1565.

    Article  PubMed  Google Scholar 

  42. Piel JE, Watkins RD, Gross P, et al.: A transrectal focused ultrasound probe for MR-guided ablation of the prostate. Proceedings of the 13th scientific meeting of the international society for magnetic resonance in medicine. Miami: International Society for Magnetic Resonance in Medicine; 2005.

    Google Scholar 

  43. Paparel P, Curiel L, Chesnais S, et al.: Synergistic inhibitory effect of high-intensity focused ultrasound combined with chemotherapy on Dunning adenocarcinoma. BJU Int 2005, 95:881–885.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to François-Joseph L. Murat.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Murat, FJ.L., Gelet, A. Current status of high-intensity focused ultrasound for prostate cancer: Technology, clinical outcomes, and future. Curr Urol Rep 9, 113–121 (2008). https://doi.org/10.1007/s11934-008-0022-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-008-0022-3

Keywords

Navigation